Floatz logo

Avzo-1418

Epithelial Tumor

Avenzo Therapeutics, Inc.Phase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

24 Active assets in the Epithelial Tumor cohort.

Asset / SponsorPhaseRating
Sorafenib
Shandong Cancer Hospital and Institute
Phase 3BB
Catumaxomab
Neovii Biotech
Phase 2/3B
Pembrolizumab
Sheba Medical Center
Phase 2B
Enadenotucirev
Akamis Bio
Phase 1/2B
Linifanib
Abbott
Phase 3B

View all 36 →

Same molecule, other indications

Avzo-1418 is also rated in:

biliary tract cancerDormant
CCC
Indicative ·
48 / 100
View asset →
lung cancerDormant
CCC
Indicative ·
48 / 100
View asset →
Locally AdvancedDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →